P-Values

A Year in the Life of GPP: What’s actually happening, and how do we know it’s working?

The Good Participatory Practice (GPP) Guidelines have been shaping and improving HIV prevention research since 2007. They provide a global reference guide for ethical and effective stakeholder engagement, helping ensure the priorities of trial participants and their communities are centered in clinical trials and broader research agendas.  

One year ago, AVAC published the Good Participatory Practice (GPP) Body of Evidence, an online clearinghouse of tools, best practices and analyses showcasing the power of GPP. Here, we bring you a report from the year since – how this clearinghouse of resources continues to demonstrate the value of GPP, and concrete examples from 2024 of GPP’s impact on major research agendas and mechanisms. Read on for highlights.

Introducing the Gears of Lenacapavir Rollout and The People’s Research Agenda

This World AIDS Day, the HIV/AIDS response stands at a crossroads, with injectable lenacapavir set to transform HIV prevention. But as the new UNAIDS report highlights, it also comes at the same time as restrictive policies, economic instability, and geopolitical challenges threaten to frustrate access and rollback so much of the progress that has been achieved over the past two decades.

Advocacy: Now more than ever

We are in a period of profound uncertainty, remarkable progress and tremendous concern—for the state of the world, for the state of global health and HIV, and for the specific work that AVAC and our partners do. We’ve seen incredible advances in biomedical prevention in 2024 with the introduction of the dapivirine vaginal ring (DVR) and injectable cabotegravir (CAB) for PrEP and the spectacular clinical trial results of injectable lenacapavir—the combination of which could transform lives if rolled out with speed, scale and equity.

Advancing Choice and Equity: New tools and a changing landscape

As a new US presidential administration takes shape, our commitment to championing choice, science, and rights remains unwavering. This critical moment demands intentional strategies to protect progress in HIV prevention and global health equity while staying true to our mission and values.

Trials to Impact

Read the latest research on injectable cabotegravir (CAB) for PrEP and find further resources for a deep dive.

The Votes Are In

In the days, months and years ahead under a new US presidential administration, advocacy for choice, freedom, science, and rights will require intentional strategies to protect hard fought gains in HIV treatment and prevention and in global health generally, and to safeguard policies and programs that advance it.

This Week at AVAC: US election, new LEN resources, STI pipeline and PrEP service delivery

As we continue to grapple with the results of the US presidential election and what this means for our work and for global health evidence- and rights-based policies and programs generally, we wanted to share a range of new tools and resources you may find helpful in your advocacy for choice, science and rights.

Today — in the US and around the world

We will all need time to process the US election results and strategize how we navigate through them in the years ahead — as individuals, as a network of partners, and as advocates for choice, science, and rights. We look forward to working with our partners in protecting hard-fought gains and assessing the potential impact on PEPFAR, Global Fund support, and on US government aid agencies.

STIWatch Newsletter, November 2024

The past few months have brought exciting developments in the field of sexually transmitted infections. WHO released the global priorities for STIs, which included the need to develop low-cost, rapid STI point-of-care tests, vaccines, and communication strategies to increase STI awareness. But we continue to see a soaring rise in STI incidence and an underfunded infrastructure for researching new treatment, prevention and testing tools.

Analysis on the Pandemic Agreement

With the latest draft of the pandemic agreement released in September showing significant weaknesses and unresolved issues, negotiators face a time crunch at their upcoming November session in Geneva to either finalize terms by mid-November or extend talks into May 2025.